Get the Stockscreener App
1.56
4.29%
-0.07
After Hours:
1.57
0.01
+0.64%
Connect Biopharma Holdings Ltd stock is traded at $1.56, with a volume of 177.04K.
It is down -4.29% in the last 24 hours and down -31.28% over the past month.
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
See More
Previous Close:
$1.63
Open:
$1.6361
24h Volume:
177.04K
Relative Volume:
1.01
Market Cap:
$98.07M
Revenue:
-
Net Income/Loss:
$-21.38M
P/E Ratio:
-4.00
EPS:
-0.39
Net Cash Flow:
$-25.19M
1W Performance:
-10.86%
1M Performance:
-31.28%
6M Performance:
+98.73%
1Y Performance:
+30.00%
1-Day Range:
$1.56
$1.69
1-Week Range:
$1.56
$1.94
52-Week Range:
$0.51
$2.86
Connect Biopharma Holdings Ltd Stock (CNTB) Company Profile
Name
Connect Biopharma Holdings Ltd
Sector
Industry
Phone
858-727-1040
Address
3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO
Compare CNTB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTB
Connect Biopharma Holdings Ltd
|
1.56 | 98.07M | 0 | -21.38M | -25.19M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Connect Biopharma Holdings Ltd Stock (CNTB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-12-25 | Initiated | H.C. Wainwright | Buy |
| Mar-04-24 | Initiated | H.C. Wainwright | Buy |
| Apr-13-21 | Initiated | Jefferies | Buy |
| Apr-13-21 | Initiated | Piper Sandler | Overweight |
| Apr-13-21 | Initiated | SVB Leerink | Outperform |
Connect Biopharma Holdings Ltd Stock (CNTB) Latest News
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Short Interest Up 204.8% in August - MarketBeat
Asthma Market to Show Paltry Growth at a CAGR of 1.95% During the Forecast Period (2025-2034) | DelveInsight - Yahoo Finance
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Sees Large Increase in Short Interest - Defense World
Connect Biopharma Announces Poster Presentations of Rademikibart at the European Respiratory Society Congress 2025 - Quiver Quantitative
New Asthma Treatment Data: Connect Biopharma's Rademikibart Shows Impact on FEV1 in Type 2 Asthma Trial - Stock Titan
Connect Biopharma completes termination of its American depositary receipt program and directly lists its ordinary shares on Nasdaq - MarketScreener
Connect Biopharma Ends ADR Program, Moves to Direct Nasdaq Listing; Shares Up Premarket - MarketScreener
Connect Biopharma Completes Termination of its American - GlobeNewswire
Biotech Connect Biopharma Completes Strategic Shift to Direct Nasdaq Listing for U.S. Growth - Stock Titan
Connect Biopharma (CNTB) to Release Quarterly Earnings on Friday - MarketBeat
COPD Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Genentech, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Sanofi, MedImmune, EpiEndo Pharma, Tetherex Pharma - Barchart.com
3 Penny Stocks To Watch With Market Caps Over $100M - simplywall.st
Connect Biopharma (CNTB) Expected to Announce Quarterly Earnings on Friday - Defense World
Connect Biopharma Holdings Limited to Participate in Upcoming Healthcare Conferences - Quiver Quantitative
Clinical-Stage Biotech Connect Biopharma Announces Key September Investor Conference Appearances - Stock Titan
We're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Rate - Yahoo Finance
Connect Biopharma (NASDAQ:CNTB) Upgraded to Hold at Wall Street Zen - Defense World
Connect Biopharma Advances Clinical Trials and Nasdaq Listing - AInvest
JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025 - azcentral.com and The Arizona Republic
Connect Biopharma Posts Q2 Revenue Drop - AOL.com
Q3 Earnings Estimate for CNTB Issued By Leerink Partnrs - Defense World
HC Wainwright Cuts Earnings Estimates for Connect Biopharma - Defense World
Connect Biopharma Reports Q2 Revenue Drop of 99.2% to $48,000, R&D Spending Increases 65.6% to $8.8mln - AInvest
Former Bengals Star Ickey Woods Expands Asthma Education Program After Son's Tragic Death - Stock Titan
Connect Biopharma Holdings Ltd SEC 10-Q Report - TradingView
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Asthma Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight - openPR.com
Connect Biopharma Holdings Limited shares rise 5.63% after-hours following Jazz Pharmaceuticals' FDA approval of Modeyso. - AInvest
Connect Biopharma Shares Rise on Plan to End ADR Program and Directly List on Nasdaq - MSN
What Makes Connect Biopharma Holdings Limited Sponsored ADR (CNTB) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Research Analysts Set Expectations for CNTB Q2 Earnings - MarketBeat
Connect Biopharma (NASDAQ:CNTB) Upgraded at Northland Capmk - Defense World
Q2 Earnings Estimate for CNTB Issued By Northland Capmk - Defense World
Connect Biopharma Holdings Limited's (NASDAQ:CNTB) Market Cap Rose US$51m Last Week; Private Equity Firms Who Hold 42% Profited and so Did Insiders - 富途牛牛
Connect Biopharma stock rating reiterated as Outperform by Northland - Investing.com Australia
Connect Biopharma appoints Jim Schoeneck to board of directors By Investing.com - Investing.com Nigeria
Connect Biopharma appoints Jim Schoeneck to board of directors - Investing.com Australia
Connect Biopharma appoints James A. Schoeneck to board of directors By Investing.com - Investing.com Nigeria
Northland starts Connect Biopharma at Outperform on chance to define new class - TipRanks
Connect Biopharma stock rises after announcing plan to terminate ADR program - Investing.com
Connect Biopharma to terminate ADR program, list ordinary shares By Investing.com - Investing.com India
Connect Biopharma to terminate ADR program, list ordinary shares - Investing.com
Connect Biopharma to Terminate ADR Program and List Ordinary Shares on Nasdaq - Nasdaq
Connect Biopharma Announces Plans to Terminate its American - GlobeNewswire
Connect Biopharma Streamlines Trading: ADRs Convert to Direct Nasdaq Shares in Major US Market Push - Stock Titan
Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference - GlobeNewswire Inc.
Connect Biopharma to Present Latest Inflammatory Disease Developments at BTIG Conference - Stock Titan
Connect Biopharma regains Nasdaq compliance with minimum bid price rule - Investing.com India
Connect Biopharma regains Nasdaq compliance with minimum bid price rule By Investing.com - Investing.com South Africa
Connect Biopharma regains Nasdaq compliance with $1 minimum bid price - Investing.com
Connect Biopharma Resolves Delisting Risk: Stock Maintains Critical $1 Threshold for Nasdaq Compliance - Stock Titan
Connect Biopharma Holdings Ltd Stock (CNTB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):